Ascletis Pharma showcases new preclinical data for its obesity pipeline, including the oral GIPR agonist ASC48 and the long-acting triple peptide agonist ASC37, at the annual ObesityWeek event.
Ascletis announces presentation of preclinical data for its drug candidates at ObesityWeek, a routine update with no financial details.
Ascletis Pharma has unveiled preclinical in vitro and in vivo data for its obesity drug candidates, ASC48 and ASC37, at the ObesityWeek conference. The presentation highlights the company's progress in developing oral small molecule GIPR agonists and long-acting triple peptide agonists.
Ascletis presented preclinical data for ASC48, an oral small molecule GIPR agonist, and ASC37, a next-generation GLP-1R/GIPR/GCGR triple peptide agonist.